Literature DB >> 20217476

Cardiovascular risk screening program in Australian community pharmacies.

Gregory M Peterson1, Kimbra D Fitzmaurice, Helen Kruup, Shane L Jackson, Rohan L Rasiah.   

Abstract

OBJECTIVE: To assess the suitability of Australian community pharmacies as cardiovascular disease risk profile screening centres and evaluate whether community pharmacists can play an important role in detecting, educating and referring screened individuals at high risk of cardiovascular disease.
SETTING: 14 Australian community pharmacies.
METHOD: Opportunistic cardiovascular disease risk profiling for members of the public aged greater than 30 years with no existing cardiovascular diseases was performed. All major cardiovascular risk factors were measured. Exercise habits, existing conditions and therapy, and family history were also assessed. The results were used to calculate each subject's 10-year risk of developing cardiovascular events, based on Framingham Risk Equations (New Zealand tables). Each subject's knowledge of cardiovascular risk factors was assessed using a multiple-choice questionnaire. Written educational materials and verbal counselling were provided. Referral to a doctor for further assessment was recommended as appropriate. The screened individuals were followed up via mailed out questionnaire. A random sample of individuals at elevated risk was phoned to assess for outcomes of the screening and referral process. MAIN OUTCOME MEASURES: Risk of developing cardiovascular disease and knowledge of cardiovascular risk factors.
RESULTS: A total of 655 individuals (71.4% female) were screened for cardiovascular disease risk factors. Ages ranged from 30 to 90 years (median: 54 years) and 14.2% were smokers. Of the individuals screened, 28.1% had a 10-year risk of developing cardiovascular disease greater than 15%, including 6.9% who had a 10-year risk above 30%. The median calculated 10-year risk of developing cardiovascular disease was 9.5%. Approximately one-third of the individuals had elevated blood pressure, and almost two-thirds were either overweight or obese. The mean total serum cholesterol was 5.31 mmol/l, with 40% of individuals having a level above 5.5 mmol/l and 20% having a high-density lipoprotein cholesterol level below 1.0 mmol/l. There was a statistically significant improvement in the knowledge of cardiovascular disease risk factors at follow-up. Almost half of the contacted high-risk subjects reported lifestyle changes or started drug therapy following re-testing by their general practitioner.
CONCLUSION: A pharmacy-based cardiovascular disease risk profile screening and education program has the potential to identify and refer many undiagnosed individuals at high risk of cardiovascular events, and help contain the burden of heart disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20217476     DOI: 10.1007/s11096-010-9379-8

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  22 in total

1.  Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association.

Authors: 
Journal:  BMJ       Date:  2000-03-11

2.  National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005.

Authors:  Andrew Tonkin; Philip Barter; James Best; Andrew Boyden; John Furler; Ken Hossack; David Sullivan; Peter Thompson; Margarite Vale; Catherine Cooper; Malia Robinson; Eleanor Clune
Journal:  Heart Lung Circ       Date:  2005-12       Impact factor: 2.975

3.  Comparison of the use of a dry chemistry analyser in primary care in Norway and the United Kingdom.

Authors:  G Thue; S Sandberg; D G Bullock
Journal:  Br J Gen Pract       Date:  1993-01       Impact factor: 5.386

4.  Evaluating the importance of information sources for preventive health care in rural Australia.

Authors:  J S Humphreys; F Rolley; H C Weinand
Journal:  Aust J Public Health       Date:  1993-06

5.  Reflotron cholesterol measurement in general practice: accuracy and detection of errors.

Authors:  M J Ball; I K Robertson; M Woods
Journal:  Ann Clin Biochem       Date:  1994-11       Impact factor: 2.057

6.  Eight compact analysis systems evaluated for measuring total cholesterol.

Authors:  L C Gregory; S H Duh; R H Christenson
Journal:  Clin Chem       Date:  1994-04       Impact factor: 8.327

7.  Evaluation of a simple method for measuring blood cholesterol levels using non-laboratory observers.

Authors:  J R Pearson; L J Dusenbury; R Bakes-Martin; M Loverde; J Johnson; R L Byyny
Journal:  Am J Med       Date:  1988-09       Impact factor: 4.965

8.  Predictors of GP service use: a community survey of an elderly Australian sample.

Authors:  A E Korten; P A Jacomb; Z Jiao; H Christensen; A F Jorm; A S Henderson; B Rodgers
Journal:  Aust N Z J Public Health       Date:  1998-08       Impact factor: 2.939

9.  The Pharmacy Diabetes Care Program: assessment of a community pharmacy diabetes service model in Australia.

Authors:  I Krass; C L Armour; B Mitchell; M Brillant; R Dienaar; J Hughes; P Lau; G Peterson; K Stewart; S Taylor; J Wilkinson
Journal:  Diabet Med       Date:  2007-06       Impact factor: 4.359

10.  Identifying at-risk patients through community pharmacy-based hypertension and stroke prevention screening projects.

Authors:  Stacy A Mangum; Kim R Kraenow; Warren A Narducci
Journal:  J Am Pharm Assoc (Wash)       Date:  2003-01
View more
  18 in total

1.  The roles of community pharmacists in cardiovascular disease prevention and management.

Authors:  J George; K McNamara; K Stewart
Journal:  Australas Med J       Date:  2011-05-31

2.  A web-based training program to support chronic kidney disease screening by community pharmacists.

Authors:  Pankti A Gheewala; Gregory M Peterson; Syed Tabish R Zaidi; Luke Bereznicki; Matthew D Jose; Ronald L Castelino
Journal:  Int J Clin Pharm       Date:  2016-06-21

3.  Patient satisfaction with a chronic kidney disease risk assessment service in community pharmacies.

Authors:  Pankti A Gheewala; Gregory M Peterson; Syed Tabish R Zaidi; Matthew D Jose; Ronald L Castelino
Journal:  Int J Clin Pharm       Date:  2018-02-13

4.  Atrial fibrillation screening in pharmacies using an iPhone ECG: a qualitative review of implementation.

Authors:  Nicole Lowres; Ines Krass; Lis Neubeck; Julie Redfern; Andrew J McLachlan; Alexandra A Bennett; S Ben Freedman
Journal:  Int J Clin Pharm       Date:  2015-07-23

5.  Community pharmacists' perceptions of services that benefit older people in New Zealand.

Authors:  June Tordoff; Shih Yen Chang; Pauline T Norris
Journal:  Int J Clin Pharm       Date:  2012-02-11

6.  Pharmacy staff opinions regarding diabetic retinopathy screenings in the community setting: findings from a brief survey.

Authors:  Miranda G Law; Stephanie Komura; Ann P Murchison; Laura T Pizzi
Journal:  Am Health Drug Benefits       Date:  2013-11

7.  The MyHealthCheckup study: Training graduate students to implement cardiovascular risk screening programs in community pharmacies.

Authors:  Hailey R Banack; Samuel Grover; Mohammed Kaouche; Sylvie Marchand; Ilka Lowensteyn
Journal:  Can Pharm J (Ott)       Date:  2012-11

8.  Awareness campaigns of atrial fibrillation as an opportunity for early detection by pharmacists: an international cross-sectional study.

Authors:  Filipa Alves da Costa; Katerina Mala-Ladova; Vivian Lee; Salvador Tous; John Papastergiou; Dale Griffiths; Marie-Camille Chaumais; Kurt E Hersberger; Reka Viola; Ema Paulino; Trudie Lobban; Lis Neubeck; Ben Freedman; Sotiris Antoniou
Journal:  J Thromb Thrombolysis       Date:  2020-05       Impact factor: 2.300

9.  Cardiovascular disease risk prevention services by pharmacists in Saudi Arabia: what do policymakers and opinion leaders think?

Authors:  Hadi A Almansour; Nouf M Aloudah; Tariq M Alhawassi; Betty Chaar; Ines Krass; Bandana Saini
Journal:  J Pharm Policy Pract       Date:  2021-05-06

10.  Screening Education And Recognition in Community pHarmacies of Atrial Fibrillation to prevent stroke in an ambulant population aged >=65 years (SEARCH-AF stroke prevention study): a cross-sectional study protocol.

Authors:  Nicole Lowres; Saul Benedict Freedman; Julie Redfern; Andrew McLachlan; Ines Krass; Alexandra Bennett; Thomas Briffa; Adrian Bauman; Lis Neubeck
Journal:  BMJ Open       Date:  2012-06-25       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.